EMCURENSEEmcure Pharmaceuticals LimitedMediumNeutral
Announced Tue, 5 May · 15:09 IST

Re-appointment of Dr. Mukund Gurjar as a Whole-time Director of the Company and Mr. Satish Mehta as Managing Director of the Company

Management Changes View source PDF

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-7.2%1-day move
₹1799.00
prior close
₹1693.10
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1-0.0-0.4-7.2-7.9-8.5-6.9-7.9-7.1-5.2-2.2+2.0
Up moveDown movePending
AI summary

The Board of Directors of Emcure Pharmaceuticals approved the re-appointment of Dr. Mukund Gurjar as a Whole-time Director for one year from August 28, 2026, and Mr. Satish Mehta as Managing Director for five years from April 1, 2027. Both re-appointments are subject to shareholder approval. Dr. Gurjar has been associated with the company since 2001 and serves as Chief Scientific Officer, bringing technical and industrial expertise. Mr. Satish Mehta founded the company in 1981 and has been Managing Director and CEO, overseeing the company's global expansion to over 70 countries. Both directors confirmed they are not debarred from holding office and are not related to other directors or KMPs.

Likely market impact

The re-appointment provides leadership continuity and stability for the company. Both key executives remain in their positions, which should be viewed positively by shareholders as it ensures continuity of strategy and operations. The long tenure of both directors (over two decades and four decades respectively) indicates established, experienced management.